{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"ORR is presented in this outcome measure as number of responders. Responders were those who had irComplete Response, IrPartial Response. Immune-Related Response Criteria: RECIST (Bohnsack et al., 2014) was used for assessment of tumor. Tumor types evaluated included Small Cell Lung Cancer (SCLC).","groups":[{"description":"Participants with SCLC who received study drug in part 2.","id":"OG000","title":"Part 2: Small Cell Lung Cancer (SCLC)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full analysis set included all participants who received at least 1 dose of study treatment. \"Number of Participants Analyzed\" refers to participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From first dose of study till the progressive disease/ death or withdrawal (maximum observation 6 years 10 months)","title":"Part 2: Overall Response Rate (ORR)- Bohnsack 2014- Disease Indication","type":"SECONDARY","unitOfMeasure":"Participants"}